Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2023-12-28 Regulatory Filings
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about the selection of a lead drug candidate and plans for preclinical development, attached as Exhibit 99.1. The document explicitly states it is a Form 8-K and includes standard SEC filing language. The length is 4460 characters, which is relatively short and typical for an 8-K filing. There is no detailed financial data or comprehensive report content, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, audit report, or other specific report type. The content is a regulatory announcement of a material event, fitting the Regulatory Filings (RNS) category, which is the fallback for Form 8-K filings that do not fit other categories.
2023-12-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 27, 2023, by Enveric Biosciences, Inc. It reports a Regulation FD Disclosure about a press release on the GLP Safety and Toxicology Program of EB-373. The document includes no financial statements or detailed financial data but rather a brief announcement and a press release attachment. The length is 4327 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the description of a Regulatory Filing (RNS) as it is a current report filing with the SEC providing a regulatory update and press release, not a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-12-27 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to the resale of common stock by a selling stockholder, Lincoln Park Capital Fund, LLC. It details the terms of a purchase agreement for up to $10 million in gross proceeds, the number of shares involved, and the plan of distribution. The document is a registration statement prospectus, which is a type of capital raising and financing disclosure. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a regulatory filing unrelated to financing. The content focuses on the capital raising transaction and share resale offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-12-06 English
Regulatory Filings 2023
Regulatory Filings
2023-12-06 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about the selection of drug candidates and plans for preclinical development, attached as Exhibit 99.1. There are no detailed financial statements or comprehensive financial analysis present. The document is not an Annual Report, Quarterly Report, or Earnings Release. It is not a proxy, governance, or management report. The content is a regulatory announcement of a material event, typical of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-05 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It is a formal communication related to a securities registration process, not a financial report or detailed filing. The document length is short (1295 characters) and it does not contain financial data or detailed report content. It is an official regulatory communication, best classified under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2023-12-04 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.